Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT addresses the clinical disease features of AD by selectively targeting the drivers of Type 2 inflammation

DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injection1

First and only therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation1,2

1

DUPIXENT selectively targets a single signalling receptor, the IL-4Rα1,5

2

DUPIXENT thereby inhibits IL-4 and IL-13 signalling1,5,6

3

DUPIXENT reduces the persistent underlying Type 2 inflammation that specifically drives AD1,5

4

DUPIXENT helps to address clinical features of AD:4,5,7

  • Skin barrier dysfunction
  • Skin lesions
  • Itch
  • Increased susceptibility to skin infections
5

DUPIXENT is a targeted immunomodulator which does not require routine lab monitoring1

Targeting Type 2 inflammation with DUPIXENT has demonstrated clinical benefits for patients and healthcare professionals

Learn more about how
DUPIXENT works


Watch video

AD, atopic dermatitis; IL, interleukin; IL-4Rα, interleukin 4 receptor alpha; ILC, innate lymphoid cells; Th, T-helper cells.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.
  2. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
  3. Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
  4. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
  5. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155– 172.
  6. D’Erme A, et al. Drug Des Devel Ther. 2017;11:1473–1480.
  7. Biedermann T, et al. Front Immunol. 2015;6:353.